Lilly Taps Chinese Biotech PepLib in Strategic Peptide Drug Deal

ZHUZHOU, China – February 03, 2026 – Global pharmaceutical giant Eli Lilly and Company has entered into a significant global research and development collaboration with Zonsen PepLib Biotech, a rapidly emerging Chinese firm specializing in peptide therapeutics. The agreement, announced today, will see the two companies join forces to discover and develop novel peptide-based drug candidates, leveraging PepLib’s proprietary discovery platforms to fuel Lilly’s formidable clinical development and commercialization engine.

Under the terms of the deal, PepLib will take the lead in the initial discovery phase, utilizing its extensive peptide libraries and technology to screen for and identify promising active molecules. Once candidates are selected, Lilly will assume responsibility for all subsequent stages, including Investigational New Drug (IND) enabling studies, global clinical trials, and worldwide commercialization. In return for its innovation, PepLib is set to receive upfront and near-term payments, in addition to being eligible for substantial development, regulatory, and sales-based milestone payments. The agreement is further sweetened by tiered royalties on potential future net sales, positioning the deal as a major financial and strategic victory for the young biotech.

Lilly's Strategic Bet on External Peptide Innovation

This collaboration is far more than a routine licensing deal for Eli Lilly; it represents a calculated move to secure its future leadership in the booming peptide therapeutics market. Already a dominant force with blockbuster GLP-1-based drugs like Mounjaro and Zepbound for diabetes and obesity, the Indiana-based company is actively seeking next-generation assets to sustain its growth and diversify its pipeline. The partnership with PepLib is a clear signal that Lilly is looking to external, specialized innovators to source cutting-edge technology.

Lilly's strategy increasingly hinges on supplementing its powerful internal R&D with high-potential external partnerships. In recent years, the company has made a series of aggressive moves to acquire or collaborate on novel platforms, including a deal with Aktis Oncology for miniprotein radiopharmaceuticals and an investment in Orbis Medicines, a startup focused on the holy grail of oral peptide drugs. The PepLib agreement fits seamlessly into this pattern, providing Lilly with access to a proven peptide discovery engine without the need for an outright acquisition.

This strategic sourcing is backed by massive capital investment in manufacturing. Lilly has committed billions to expanding its peptide production capabilities, including a state-of-the-art facility in Ireland and a new $3.5 billion plant in Pennsylvania dedicated to injectable medicines. These facilities require a steady stream of new drug candidates to justify their scale, and the collaboration with PepLib is designed to help fill that future pipeline with innovative molecules across Lilly's core therapeutic areas.

A Landmark Achievement for Zonsen PepLib and Chinese Biotech

For Zonsen PepLib, this agreement marks a pivotal moment. Founded in just 2017, the Zhuzhou-based company has rapidly established itself as a significant player in peptide discovery, driven by a heavy focus on R&D that engages over 80% of its 200-plus employees. The partnership with a global leader of Lilly’s stature serves as a powerful international validation of its proprietary technology platforms.

“This collaboration further validates PepLib’s innovative and differentiated peptide R&D platforms,” said Lei Chen, Chairman and Co-founder of PepLib, in a statement. “As a global leader across multiple disease areas, Lilly is our valued partner. We look forward to the close collaboration to develop novel therapeutic strategies for diseases and deliver benefits to patients worldwide.”

The Lilly deal is not an isolated success but rather the latest and most significant in a series of high-profile agreements for PepLib. Just last month, the company announced a worldwide license agreement with Novartis for a peptide-based asset in radioligand therapy, a deal that included a $50 million upfront payment. This pattern of attracting top-tier pharmaceutical partners underscores the perceived value and sophistication of PepLib’s technology. It also reflects a broader trend within the global pharmaceutical landscape: the rise of Chinese biotechs as sources of genuine, world-class innovation, moving far beyond their historical role in manufacturing and generics.

Unlocking the Power of Peptides: From Discovery to Clinic

The core of the collaboration lies in PepLib's advanced technological capabilities. The company has developed what it calls “robust and diverse proprietary peptide libraries,” which are the foundation of its discovery process. These are not standard chemical libraries but highly specialized collections, including those built with Peptide Information Compression Technology (PICT), as well as nano-cyclic and animal toxin peptide libraries. This diversity allows for the exploration of a vast chemical space to find peptides with ideal therapeutic properties.

Beyond just libraries, PepLib has built platforms to develop complex, next-generation peptide modalities. These include Peptide Radionuclide Conjugates (PRCs), which attach radioactive isotopes to peptides for targeted cancer therapy or imaging, and Peptide Drug Conjugates (PDCs), which use peptides to deliver a toxic payload directly to diseased cells. This expertise in sophisticated drug constructs makes PepLib an especially attractive partner for companies looking to move into precision medicine.

This scientific prowess is entering a market with explosive potential. The global peptide therapeutics market, valued at over $117 billion in 2024, is projected to more than double to over $260 billion by 2030. This growth is fueled by the inherent advantages of peptides—high specificity, potency, and a favorable safety profile—which make them ideal for treating complex chronic conditions. The synergy in this partnership is clear: PepLib provides the high-tech discovery engine to find novel peptides, while Lilly provides the immense resources and expertise needed to navigate the long and arduous path of clinical development and global commercialization.

Charting the Course in High-Value Therapeutic Areas

While the specific targets of the collaboration remain undisclosed, the strategic priorities of both companies point toward two key areas: oncology and cardiometabolic diseases. Both are primary focus areas for PepLib, and both are central pillars of Lilly’s long-term growth strategy. In oncology, PepLib’s expertise in PRCs and PDCs aligns perfectly with Lilly’s recent investments in radiopharmaceuticals and precision cancer treatments. A partnership could yield highly targeted therapies for difficult-to-treat tumors.

In the cardiometabolic space, Lilly’s unparalleled success with GLP-1 agonists creates a high bar, but also a pressing need for what comes next. PepLib's platforms could uncover novel peptides that act on new metabolic pathways or offer improved efficacy or delivery mechanisms over existing treatments. The collaboration could also venture into other areas of mutual interest, such as neurodegeneration and immunology, where peptide-based approaches hold significant promise.

By tasking Lilly with leading IND-enabling studies, the agreement confirms that the collaboration will focus on early-stage discovery, aiming to create a portfolio of new drug candidates from the ground up. This long-term vision, combining PepLib’s innovative spark with Lilly’s industrial-scale power, has the potential to redefine treatment paradigms and ultimately deliver a new generation of medicines to patients around the globe.